Taking the benefits of DAFNE to the UK and beyond  to type 1
diabetes. That caught their attention. Berger was describing was
a treatment programme that improved diabetes control in real
terms. In contrast to the Diabetes Control and Complications
Trial (DCCT ), then still running, this was a programme that
delivered lower average blood glucose concentrations and HbA1c
and reduced the risk of severe hypoglycaemia. The DCCT seemed to
show that this was not possible: the lower the HbA1c, the lower
the risk of vascular complications but with a much higher risk
of hypoglycaemia. Just over a year later, teams from King’s
College Hospital London, Sheffield University and North Tyneside
Hospital, all in the UK, visited Dusseldorf, Germany, to find
out what Professor Berger’s team was doing.